Lighthouse Pharmaceutical Biotechnology plans to fully acquire Conflux Blockchain related assets.

According to Gate News bot, PANews reported that Pioneer Pharmaceutical Biotechnology Co., Ltd. (00399) announced on July 1 that it has signed a memorandum of understanding to acquire all equity of the target company, which includes the Conflux Blockchain-related assets that the target company will acquire in the future.

The acquisition consideration will be paid in cash, company shares, or convertible bonds, and the final amount will be specified in the formal agreement. The memorandum of understanding is valid for 12 months, during which the seller must comply with exclusivity terms.

Pioneer Pharma stated that this move is a strategic layout for entering the Blockchain technology field and achieving business diversification. Currently, the transaction is pending the signing of a formal agreement. The company will release relevant announcements in accordance with listing rules.

Additionally, the Hong Kong market was closed on that day due to the anniversary of the establishment of the Hong Kong Special Administrative Region.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)